Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Vimian Group in connection with its rights issue
Mandate

Vinge has advised Vimian Group in connection with its rights issue

March 12, 2024

Vinge has advised Vimian Group AB (publ) in connection with a partly guaranteed rights issue which will provide Vimian with issue proceeds of SEK 1,633 billion before deduction of transaction costs.

Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. At Vimian, one believes that every animal deserves the best available care. Vimian brings pioneering businesses together to make the market’s most innovative offerings accessible to more animal health professionals and pet owners.

Vinge’s team consisted of Dain Hård Nevonen,  Linnéa Sellström, Anna Svensson, Michaela Ådén and Alexander Rüdén.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of SEK 350 million before transaction costs.
April 22, 2026

Vinge has advised Alder on the establishment of Alder Strategic Opportunities Fund I and on a fund credit facility agreement in connection with the fundraising

 Vinge has advised Alder on the establishment of the continuation fund Alder Strategic Opportunities Fund I AB. In connection with the establishment, the fund acquires the portfolio companies SI and SMG from Alder II. Vinge also advised Alder on the entering into of a fund credit facility agreement with SEB.
April 20, 2026

Vinge has advised IK Partners in connection with the acquisition of Selatek

 Vinge has advised IK Partners (“IK”) in connection with IK X Fund’s acquisition of SELATEK Holding AB (“Selatek”), a leading Swedish technical installation platform, from Amplio Private Equity AB and the minority shareholders.
April 20, 2026